Phase I dose-escalation study of the tolerability and pharmacokinetics of a weekly 24h infusion of rigosertib in patients with advanced solid tumours.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 08 May 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

23 Feb 2012 Actual initiation date (June 2006), additional lead investigator (Sridhar Mani) and actual patient no 42 added as reported by ClinicalTrials.gov.
23 Feb 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health).
23 Feb 2012 Actual end date (November 2011) added as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com